# Event Update PSP Projects Ltd



### New order wins lead to earning upgrades

PSP Projetcs (PSP) over the last two days announced order wins (including L1) worth ~INR 2,500 cr. With these order wins, FY21 turned out to be the best ever order addition year for the company. Currently, PSP is sitting on a historic high orderbook of ~INR 5,000 cr and now has revenue visibility of ~4 years which is again at historic high levels. We are upgrading our estimates to accommodate these new orders. We believe, Revenue of the company will grow at 23% CAGR over FY20-23E against our earlier estimate of 15%. We also upgrade our EBITDA and PAT estimates by 20%/26% and 18%/24% for FY22/23E. Due to higher earning visibility and upgarde in earnings, we upgrade our price target to INR 700 and maintain BUY.

### Recent Order Announcements makes FY21 as historic best year of Order Addition

We were concerned about PSP's muted oreder addition as till 9MFY21 company had received orders of only INR 200 cr. However, over the last two days, PSP announced strong orders (including L1) worth ~INR 2,500 cr. With this, total order book reached to historic high levels of INR 5,000 cr and now has revenue visibility of ~4 years which is again at historic high for the compay. Also, with these wins, FY21E turns out to be the best ever order addition year for PSP with total declared order wins of INR 2,700 cr. as of today. The recent order wins includes INR 236 cr order for an Institutional project at Gujarat, INR 590 cr project from a private developer at Ahmedabad and L1 bidder for projects totalling INR 1,670 cr for construction of medical colleges at multiple locations at Uttar Pradesh.

### We are revising our Earnings Estimates by 18%/24% of FY22/23E

Based on the recent wins, we are upgrading our estimates. We believe, Revenue of the compnay will grow at 23% CAGR over FY20-23E against our earlier estimate of 15%. We upgarde our EBITDA estimates by 20%/26% for FY22/23E. Despite hike in raw material prices, the company able reach 12% EBITDA margin in Q3FY21 and we expect the EBITDA margin to cross 13% in FY23E. We also upgrade our PAT estimates by 18%/24% for FY22/23E.

### Cash conversion cycle remaines key monitarable

With the new orders, PSP's orderbook share tilted more towards government projetcs where Cash Conversion cycle is not as good as private and industrial projetcs. PSP currently has 54% of the orderbook coming from Govt. projetcs which will structurally put upward pressure on NWC cycle and company is not expected go back to its previous NWC cycle of 10-15 days. We ramined confident on project selection capability of the company but will continue to monitor the NWC cycle going forard.

### Reiterate 'BUY' with upgrade in target price to INR 700

At CMP of INR 460, the stock is trading at 10x / 7x of FY22E / FY23E EPS. Due to higher earning visibility and upgarde in earnings we upgrade the price target to INR 700 and maintain BUY.

(INR Cr)	FY20	FY21E	FY22E	FY23E
Revenues	1499	1267	2030	2784
EBIDTA	191	136	249	369
EBIDTA Margin	13%	11%	12%	13%
PAT	128	85	165	249
PAT Margin	9%	7%	8%	9%
Diluted EPS (INR)	36	24	46	69
Diluted PE (x)	11	19	10	7
EV/EBIDTA	7	11	6	3
ROE(%)	28%	16%	23%	26%

### Debashish Mazumdar

**Research Analyst** 

debashish.mazumdar@edelweissfin.com

**CMP INR: 460** 

Rating: BUY
Target Price INR: 700

Upside: 52%

Bloomberg:	PSPPL:IN
52-week range (INR):	232 / 540
Share in issue (cr):	3.6
M cap (INR cr):	1,607
Promoter	73.28

Date: February 5, 2021



### **Financials**

Income Statement (Consolidated)					(INR cr)
Year to March	FY19	FY20	FY21E	FY22E	FY23E
Income from operations	1,050	1,499	1,267	2,030	2,784
Direct Expenses	416	535	456	751	1,023
Employee Cost	43	59	54	76	97
Other Expenses	443	714	621	954	1,294
Total operating expenses	902	1,309	1,131	1,782	2,415
EBITDA	149	191	136	249	369
Depreciation and amortisation	24	27	31	43	56
EBIT	124	164	105	205	313
Interest expenses	10	15	10	6	6
Other income	23	24	18	20	25
Profit before tax	137	173	113	220	332
Provision for tax	48	45	28	55	83
Core profit	89	128	85	165	249
Extraordinary items	0	0	0	0	0
Profit after tax	89	128	85	165	249
Minority Interest	0	0	0	0	0
Share from associates	-0	-0	0	0	0
Adjusted net profit	89	128	85	165	249
Equity shares outstanding (Crs)	3.6	3.6	3.6	3.6	3.6
EPS (INR) basic	24.8	35.6	23.6	45.8	69.3
Diluted shares (Crs)	3.6	3.6	3.6	3.6	3.6
EPS (INR) fully diluted	24.8	35.6	23.6	45.8	69.3
Dividend per share	5.0	0.0	0.0	0.0	0.0
Dividend payout (%)	20.2	0.0	0.0	0.0	0.0
Common size metrics- as % of net revenues					
Year to March	FY19	FY20	FY21E	FY22E	FY23E
Operating expenses	85.9	87.3	89.3	87.8	86.8
Depreciation	2.3	1.8	2.4	2.1	2.0
Interest expenditure	0.9	1.0	0.8	0.3	0.2
EBITDA margins	14.1	12.7	10.8	12.3	13.3
Net profit margins	8.5	8.5	6.7	8.1	9.0
Growth metrics (%)					
Year to March	FY19	FY20	FY21E	FY22E	FY23E
Revenues	39.7	42.7	(15.5)	60.3	37.1
EBITDA	42.0	28.3	(28.6)	82.6	48.3
РВТ	34.1	26.1	(34.6)	94.0	51.2
Net profit after minority interest	35.2	43.7	(33.7)	94.0	51.2
EPS	35.2	43.7			51.2



### **Financials**

Balance Sheet (Consolidated)			(INR cr)		
As on 31st March	FY19	FY20	FY21E	FY22E	FY23E
Equity share capital	36	36	36	36	36
Warrants	0	0	0	0	0
Reserves & surplus	334	418	504	669	919
Shareholders funds	370	454	540	705	955
Borrowings	30	78	53	28	28
Minority interest	1	1	1	1	1
Sources of funds	401	533	593	734	983
Gross block	167	197	247	347	447
Depreciation	64	90	121	165	220
Net block	103	106	126	182	226
Capital work in progress	0	3	2	2	2
Total fixed assets	103	110	127	184	228
Goodwill	0	0	0	0	0
Non Current Assets	64	156	161	166	171
Inventories	75	97	83	188	256
Sundry debtors	148	235	204	338	464
Cash and equivalents	248	197	175	205	406
Loans and advances	59	135	180	190	200
Other current assets	37	34	0	0	0
Total current assets	567	698	643	922	1,326
Sundry creditors and others	159	217	338	539	743
Other Current Liabilities	162	212	0	0	0
Provisions	0	1	0	0	0
Total CL & provisions	322	430	338	539	743
Net current assets	245	269	304	383	583
Net Deferred tax	0	0	0	0	0
Misc expenditure	0	0	0	0	0
Uses of funds	401	533	593	734	983
Book value per share (INR)	111	148	165	204	273

Cash flow statement					(INR cr)
Year to March	FY19	FY20	FY21E	FY22E	FY23E
Net profit	89	128	85	165	249
Add: Depreciation	24	27	31	43	56
Add: Interest net of tax	6	11	7	4	4
Add: Deferred tax	0	0	0	0	0
Add: Others	28	20	30	30	30
Gross cash flow	147	186	153	242	339
Less: Changes in W. C.	120	167	150	100	100
Operating cash flow	28	19	3	142	239
Less: Capex	47	30	50	100	100
Less: Investment in subsidiaries	0	0	0	0	0
Free cash flow	-19	-11	-47	42	139



### **Financials**

### **Profit & Efficiency Ratios**

Year to March	FY19	FY20	FY21E	FY22E	FY23E
ROAE (%)	24%	28%	16%	23%	26%
ROACE (%)	31%	31%	18%	28%	32%
Debtors (days)	51	57	59	61	61
Current ratio	1.7	1.6	1.9	1.7	1.8
Gross Debt/Equity	0.0	0.0	0.1	0.0	0.0
Inventory (days)	26	24	24	34	34
Payable (days)	55	53	54	52	51
Cash conversion cycle (days)	22	28	29	43	43
Gross Debt/EBITDA	0.0	0.0	0.4	0.1	0.1
Net debt/Equity	(0.7)	(0.4)	(0.2)	(0.3)	(0.4)

### **Valuation Parameters**


Year to March	FY19	FY20	FY21E	FY22E	FY23E
Diluted EPS (INR)	24.8	35.6	23.6	45.8	69.3
Y-o-Y growth (%)	35.2	43.7	(33.7)	94.0	51.2
CEPS (INR)	31.5	43.0	32.2	57.8	84.8
Diluted P/E (x)	16.1	11.2	19.5	10.0	6.6
Price/BV(x)	3.9	3.2	3.1	2.3	1.7
EV/Sales (x)	1.1	0.8	1.2	0.7	0.5
EV/EBITDA (x)	8.0	6.5	11.3	5.9	3.5
Diluted shares O/S	3.6	3.6	3.6	3.6	3.6
Basic EPS	24.8	35.6	23.6	45.8	69.3
Basic PE (x)	16.1	11.2	19.5	10.0	6.6
Dividend yield (%)	1%	0%	0%	0%	0%



**Edelweiss Broking Limited**, 1st Floor, Tower 3, Wing B, Kohinoor City Mall, Kohinoor City, Kirol Road, Kurla(W) Board: (91-22) 4272 2200

### Vinay Khattar Head Research vinay.khattar@edelweissfin.com

Rating	Expected to
Buy	appreciate more than 15% over a 12-month period
Hold	appreciate between 5-15% over a 12-month period
Reduce	Return below 5% over a 12-month period





### Disclaimer

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its Associates (list available on www.edelweissfin.com) are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

Broking services offered by Edelweiss Broking Limited under SEBI Registration No.: INZ000005231; Name of the Compliance Officer: Mr. Brijmohan Bohra, Email ID: complianceofficer.ebl@edelweissfin.com Corporate Office: Edelweiss House, Off CST Road, Kalina, Mumbai - 400098; Tel. 18001023335/022-42722200/022-40094279

This Report has been prepared by Edelweiss Broking Limited in the capacity of a Research Analyst having SEBI Registration No.1NH000000172 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject EBL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. EBL reserves the right to make modifications and alterations to this statement as may be required from time to time. EBL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. EBL is committed to providing independent and transparent recommendation to its clients. Neither EBL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures of interest s

EBL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the EBL to present the data. In no event shall EBL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the EBL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

EBL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. EBL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with EBL.

EBL or its associates may have received compensation from the subject company in the past 12 months. EBL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. EBL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or EBL's associates may have financial interest in the subject company. EBL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No EBL has financial interest in the subject companies: No

EBL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

EBL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

### Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimer for U.S. Persons



### Disclaimer

Edelweiss is not a registered broker – dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition Edelweiss is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Edelweiss, including the products and services described herein are not available to or intended for U.S. persons.

This report does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.

Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

#### Additional Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

#### Additional Disclaimer for Canadian Persons

Edelweiss is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Edelweiss, including the products and services described herein, are not available to or intended for Canadian persons.

This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.

### Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations)

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups — Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited ("Edelweiss") in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No.INH00000172.